The Important Environment
National and International Activities
The international cancer genomics field is considered highly competent and advancing rapidly. NCGC have fruitful collaborations with organisations and institutions world wide.
NCGC arranges symposium on “Nordic Model for Personalized Medicine”, Oslo 2017.
“Close to the patient” in US
The Center for Translational and Public Health Genomics (CTPHG), at MD Anderson Cancer Center, was created in order to overcome some of the challenges with cancer treatment. The program has been designed to cover all types and grades of cancers the occur in the general population. The program includes all types of cancer patients; high-risk patients as well as cancer survivors.
Research at the Univeristy of Oxford
Professor Bass Hassan is a front figure within Personalized Cancer Medicine in England. Hassan held a talk at the Cancer Genomics Conference at Losby in march 2014, on the topic “personalized medicine in practise”. Benefits and drawbacks were discussed, including the effects on economics.
Europe Does It Better: Molecular Testing across a National Health Care System—The French Example
The French National Cancer Institute (Inca) and the French Health Department have established a national network of 28 regional Molecular Genetics Centers. Selected molecular tests are performed free of charge for the patient. In addition, a program has been set in place with the aim to launch the use of new targeted therapies and to accelerate access to new drugs and the use of experimental treatments. The initiative has been running for 5 years, and so far appears to be a success. Rapid implementation of molecular testing using new biomarkers is another key focus ongoing.
(Norsk) Genomstudier i Australia
(Norsk) The Kinghorn Cancer Institute i Sydney har igangsatt store studier der arvestoffet i friske og syke individer sekvesneres, for å finne nye mekanismer for sykdomsutvikling og kreftrisiko. NCGC/NoSarC samarbeider med dem.
International Cancer Genome Consortium
ICGCs aims to describe in detail the genomic, transcriptomic and epigenetic changes in the 50 different cancer types and/or subtypes, which are considered the most clinically and publicly relevant through out the world.
This is a national network including researchers and clinicians, working within cancer genomics. The over all aim is to improve cancer treatment as quickly as possible. Bringing clinicians, researchers and the decission-makers within Public Health and Politics together, it becomes possible to more clearly see the challenges we are facing. We need to implement new strategies within diagnostics and patient treatment. The changes should be based on research findings and must be performed in a systematic manner. Nasjonal Kreftsatsing is approved by Nasjonal Samarbeidsgruppe for medisinsk og helsefaglig forskning (NSG) for the period 2012 – 2016.